Tumoral angiogenesis and breast cancer
- 115 Downloads
Breast cancer (BC) is the most common neoplasm in women in Western countries. Tumoral angiogenesis (TA) is essential for the growth and spread of BC cells. There are at least 6 different angiogenic growth factors associated with TA in BC. The major mediator of TA is vascular endothelial growth factor (VEGF), a homodimeric heparin-binding glycoprotein. VEGF signals through VEGF receptor-2 (VEGFR-2), the major VEGF signalling receptor that mediates sprouting angiogenesis. Recently, different antiangiogenic agents have shown efficacy in the treatment of advanced BC. Bevacizumab, a humanised monoclonal antibody against VEGF, in combination with taxanes improves progression-free survival and overall response rate in first-line therapy. Other new antiangiogenic agents, called multi-kinase inhibitors (sunitinib and pazopanib), are under investigation. Finally, a schedule of treatment called metronomic chemotherapy, with antiangiogenic activity, has also demonstrated efficacy in the treatment of advanced BC.
KeywordsVEGF Sunitinib Bevacizumab Metronomic chemotherapy Pazopanib
Unable to display preview. Download preview PDF.
- 2.Khosravi P (2006) Angiogenesis y neoplasias. An Med Interna 23:355–356Google Scholar
- 19.Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672–4678PubMedCrossRefGoogle Scholar
- 20.Cristofanilli M, Valero V, Mangalik A et al (2008) A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol 26:abstr 1012Google Scholar
- 22.Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMedGoogle Scholar
- 26.Slamon D, Gomez HL, Kabbinavar F et al (2008) Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer. J Clin Oncol 26:abstr 1016Google Scholar
- 28.Khosravi P, Pérez-Manga G (2007) Una nueva estrategia terapéutica en el cáncer de mama: quimioterapia metronómica. An Med Interna 24:261–262Google Scholar